Adjuvant Chemotherapy Trial of S-1 for breast cancer with ER-positive and HER2-negative.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 21 Aug 2017
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary)
- Indications Breast cancer
- Focus Registrational; Therapeutic Use
- 21 Aug 2017 Planned number of patients changed from 1400 to 1860.
- 30 Sep 2015 Status changed from recruiting to active, no longer recruiting, as reported by University Hospital Medical Information Network - Japan.
- 26 Jan 2012 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan. (Parent trial: UMIN000003969)